



RESULTS 3rd QUARTER 2006

Structural turnover and profit growth in 3rd quarter

- **Consumer Health division (OTC) performs well in a traditionally calm third quarter; accelerated implementation of restructurings at Arseus (B2B).**
- **A number of important strategic projects (preparing the autonomy of Arseus, acquisition Bittner Pharma) are running in parallel.**
- **Jan Cassiman and Ger van Jeveren – respectively CEO of the OTC division and Arseus – are nominated as member of the Board of Directors.**

Nazareth (Belgium), 23 November 2006 – In the third quarter 2006, Omega Pharma has generated a net result of EUR 13.0 million (+3.5%) on a turnover of EUR 226.9 million (+6.2%). In parallel, the company has invested in preparing the organization for the future.

Non-audited, consolidated results IFRS (in EUR thousands)	3rd quarter		
	2006	2005	Evolution
Net turnover	226,900	213,561	+6.2%
Recurring operating cash flow (REBITDA) ⁽¹⁾	30,710	28,567	+7.5%
Depreciations and amortizations (DA)	5,060	4,592	+10.2%
Recurring operating result (REBIT)	25,650	23,975	+7.0%
Non-recurring items	-3,582	-2,589	
Operating cash flow (EBITDA)	27,128	25,979	+4.4%
Operating result (EBIT)	22,068	21,385	+3.2%
Financial result	-7,201	-6,871	+4.8%
Profit before taxes (EBT)	14,867	14,514	+2.4%
Taxes	1,893	1,976	-4.2%
Net profit	12,974	12,538	+3.5%
Recurring net profit for the period ⁽²⁾	16,004	14,766	+8.4%
Recurring net cash flow ⁽³⁾	21,065	19,358	+8.8%
Weighted average number of shares ⁽⁴⁾	25,823,983	26,205,201	
Data per share, in EUR			
Net profit per share ⁽³⁾	0.50	0.48	+4%
Recurring net profit/share	0.62	0.56	+11%
Recurring cash flow/share	0.82	0.74	+11%

(1) Operating result adjusted for non-recurring elements, plus depreciations and amortizations

(2) Net profit for the period, adjusted for non-recurring items and related taxes

(3) Recurring net profit for the period plus depreciations and amortizations

(4) Calculated on the basis of the weighted average of the number of shares, after deduction of the number of treasury shares

COMMENTS WITH THE CONSOLIDATED FINANCIAL ACCOUNTS FOR THE 3RD QUARTER

Third quarter brings recovery from difficult second quarter

The consolidated turnover has grown by 6% versus the third quarter 2005, thus largely compensating the sales decline (-3%) of the second quarter. For the first nine months of 2006, the turnover is 4% above the level of the same period last year.

The gross margin amounts to 53.0% versus 51.1% in the third quarter 2005 and 52.9% in the first half of this year. Although the third quarter is traditionally less strong, a slight margin improvement could be achieved this year. Opposed to the third quarter 2005, when the marketing expenses were put at a lower level, they have been maintained at the average annual level in this quarter. Major efforts have also been made in the field of R&D and product innovation, thus supporting the further development of the OTC brands in the future.

Thanks to the effects of the Vitamin O program, the recurring operating cash flow grew slightly faster (+7%) than the turnover (+6%). The REBITDA amounts to EUR 30.7 million and represents 13.5% of turnover – versus 13.4% in the third quarter 2005.

Depreciations and amortizations (DA) have evolved a little stronger than the recurring operating cash flow, resulting in a recurring operating profit (REBIT) of EUR 25.7 million – i.e. 11.3% of turnover.

This quarter, the extraordinary charges related to a number of strategic projects and restructurings, are shown separately. They refer to the transformation of the sales teams and the related back-office functions in France, which involved a number of changes and additional training during this quarter. At Arseus, the restructurings will largely be finalized by the end of December, thus enabling the organization to start 2007 at full strength. The charges related to the legal structure in preparation of the split-off of Arseus, are also included. In addition, a number of extraordinary counselling costs, related to the acquisition of Bittner Pharma, have been included. By isolating these extraordinary charges, a clearer view is provided on the underlying operational performance.


The financial result is at a comparable level to last year.

SEGMENT REPORTING; FIGURES PER BUSINESS UNIT

Evolution of the turnover

Non-audited, consolidated management figures IFRS (in EUR million)	Turnover third quarter		
	2006	2005	Evolution
Omega Belgium	50.0	44.7	+12%
Omega France	34.8	34.2	+2%
Omega Europe	80.3	70.5	+14%
Consumer Health (OTC)	165.1	149.4	+11%
Fagron Group	22.0	21.3	+3%
OmegaSoft	5.7	6.6	-14%
Omega Dental	22.7	21.7	+5%
Omega Medical	11.4	14.6	-22%
Professional Health (B2B)	61.8	64.2	-4%
Total Omega Pharma	226.9	213.6	+6%

Distribution of 3rd quarter 2006 turnover



Evolution of the recurring operating cash flow (REBITDA)

Non-audited, consolidated management figures IFRS – (in EUR million)	REBITDA third quarter			
	REBITDA 2006	Margin* 2006	REBITDA 2005	Evolution 06/05
Omega Belgium	5,1	10,2%	4,5	+13%
Omega France	2,7	7,8%	1,9	+42%
Omega Europe	17,5	21,8%	16,0	+9%
Consumer Health (OTC)	25,3	15,3%	22,4	+13%
Fagron Group	3,3	14,9%	3,3	+0%
OmegaSoft	1,7	29,8%	2,0	-15%
Omega Dental	1,7	7,5%	1,7	+0%
Omega Medical	0,9	7,9%	1,1	-18%
Professional Health (B2B)	7,6	12,3%	8,1	-6%
REBITDA Omega Pharma	30,7	13,5%	28,6	+7%

* % of turnover

CONSUMER HEALTH (OTC): consistent performance of Omega Belgium and Europe – sales uptake in France has immediate effect on profitability

The growth of the turnover in the third quarter amounts to 11% and the recurring operating cash flow has increased by 13%. The quarterly turnover of the Star Brands grew 15% to EUR 37.0 million, thus representing 29% of the OTC sales¹ of the quarter.

- The turnover of Omega Belgium increased by 12% and the recurring operating cash flow by 13%. This is a strong performance, considering the 22% sales growth of lower-margin generic medicines. (In Belgium, Omega Pharma distributes the generic pharmaceuticals of Eurogenerics). The solid sales growth of the Star Brands (+29%) and an on-going cost awareness have contributed to the increased cash flow.
- Omega France has been able to translate the 2% sales uptake, following the sharp decline in the second quarter (-18%) into an improved profitability. The recurring operating cash flow is 42% above the level of the third quarter 2005. This performance illustrates that the new sales organization has made an excellent start. It remains for fourth-quarter results to confirm the structural improvement in this area. The further improvement of the REBITDA margin also remains priority.
- Omega Europe posts a 14% increase in turnover for the third quarter and a 9% growth of the recurring operating cash flow. For a variety of reasons, including holiday planning, it is much more difficult in the third quarter to achieve the usual level of efficiency. Moreover, the future-oriented marketing efforts of this quarter are largely concentrated in this business unit. With a REBITDA margin of 21.8% Omega Europe remains the business unit where the value of Omega Pharma's business model is best demonstrated.

ARSEUS (B2B): Q2 sales decrease is already significantly lowered and REBITDA evolves closer to turnover

Logically, the termination of non-profitable distribution contracts during the first half of the year has a structural impact on the turnover. However, the sales decrease is already significantly lowered in the third quarter.

The development of the Arseus business plan and the implementation of a number of restructurings have already resulted in a better alignment between the evolution of the REBITDA and the turnover.

In the third quarter Arseus has started to acquire new distribution activities that fit into the new business model and that will contribute as of the fourth quarter to both turnover and operating profit.

The Arseus management expects to reach in the course of the fourth quarter the turning point from which it can demonstrate sales growth again. Arseus is ready for its reference year 2007 and for the split-off in 2008.

¹ Excluding the turnover from generic medicines in Belgium

OTHER RELEVANT EVENTS

Closing of the Bittner Pharma acquisition expected

Omega Pharma still expects the closing of the Bittner Pharma acquisition end 2006, beginning 2007. This implies that Bittner Pharma can probably be included in consolidation as of 1st January 2007. Consequently, Omega Pharma could start to actively target the fast-growing OTC markets in Central and Eastern Europe in 2007.

Nomination of Jan Cassiman and Ger van Jeveren as director

Last week, the convocation to the Extraordinary General Shareholder Meeting of 14 December 2006 has been published. At this event, the Board of Directors will propose to appoint Jan Cassiman, CEO for OTC, and Ger van Jeveren, CEO Arseus, as director.

This nomination is part of the legal-administrative preparation process to transform Arseus and Omega Pharma OTC into two autonomous companies. At present all legal entities of the Arseus division have been structured under one legal umbrella entity.

PROGNOSES²

The figures for the third quarter reconfirm Omega Pharma's potential to achieve an average 6% organic sales growth with moderately increasing REBITDA margins.

Throughout 2006, necessary reorganization measures have been implemented — both in France and in Arseus. In the third quarter, the effects of these measures have already come to the fore to a limited degree, and they should gradually come to stronger expression.

Omega Pharma still expects to achieve its long-term objective of 6% sales growth in the fourth quarter.

Omega Pharma will endeavour to finalize the current restructuring plans in the fourth quarter. Other strategic projects, including the closing of the Bittner Pharma acquisition and the preparation of the Arseus split-off, will receive full attention. 2007 is a promising year – both for the Consumer Health division as for Arseus.

For more information, please contact:

Chris.Vanraemdonck@omega-pharma.be

0032/9/381.03.31 — 0032/499/58.55.31

Financial calendar

Thursday 18 January 2007	:	Sales Flash fourth quarter 2006
Thursday 15 March 2007	:	Results 2006

² Disclaimer: This press release contains forward-looking information which is based on current internal estimates and expectations as well as market expectations. Forward-looking statements contain inherent risks and apply exclusively on the date they are made. The actual results may differ substantially from those included in the forward-looking statements.